Strong results for Keytruda in head and neck cancer
MSD’s Keytruda improved overall survival by up to 39% in first-line head and neck cancer, new results show.
Interim data from KEYNOTE-048 showed Keytruda monotherapy improved overall survival (OS) by 39% in patients whose tumors expressed PD-L1 with Combined Positive Score (CPS) greater-than or equal to 20, and by 22% in patients with CPS greater than or equal to 1, compared to the current standard of care.
In addition, Keytruda in combination with chemotherapy demonstrated improved OS by 23 percent regardless of PD-L1 expression.
Read more: http://www.pharmatimes.com/news/strong_results_for_keytruda_in_head_and_neck_cancer_1256643
Interim data from KEYNOTE-048 showed Keytruda monotherapy improved overall survival (OS) by 39% in patients whose tumors expressed PD-L1 with Combined Positive Score (CPS) greater-than or equal to 20, and by 22% in patients with CPS greater than or equal to 1, compared to the current standard of care.
In addition, Keytruda in combination with chemotherapy demonstrated improved OS by 23 percent regardless of PD-L1 expression.
Read more: http://www.pharmatimes.com/news/strong_results_for_keytruda_in_head_and_neck_cancer_1256643
